Which company holds keytruda's patents?

Who is the patent holder for Keytruda?

Keytruda is a brand name for pembrolizumab, a medication used to treat various types of cancer. The patent holder for Keytruda is Merck & Co., Inc.[1] Merck & Co. acquired the rights to develop and commercialize pembrolizumab through a licensing agreement with Ono Pharmaceutical Co. Ltd. in 2006.

According to DrugPatentWatch.com, the U.S. patent for pembrolizumab (Keytruda) is held by Merck & Co., Inc. and expires in 2028.[2] However, it's essential to note that this is not the only patent related to Keytruda, and the expiration date may change as new patents are filed.

How does Merck's patent on Keytruda affect competition in the market?

As a result of the patent, Merck & Co. has exclusive rights to manufacture and sell Keytruda until the patent expires. This has allowed the company to maintain a dominant position in the market for non-small cell lung cancer (NSCLC) and other cancer types treated with pembrolizumab. However, the patent's expiration will open up the market to potential competitors, and biosimilars or generic versions of Keytruda may become available.

Will biosimilars enter the market before the patent expires?

The U.S. Biosimilars Council and other organizations are advocating for greater access to affordable cancer treatments, including biosimilars. However, the process of developing and marketing biosimilars is complex, and regulatory hurdles must be cleared before these alternatives can enter the market. It is likely that biosimilars will be approved after the patent expires, but the exact timeline depends on various factors, including the FDA's approval process and market demand.

Can biosimilars challenge Keytruda's position in the market?

Biosimilars can challenge Keytruda's position in the market by offering more affordable alternatives with comparable efficacy and safety profiles. However, a successful biosimilar will need to demonstrate non-inferiority to Keytruda through clinical trials, which can be costly and time-consuming. Additionally, Merck & Co. may continue to innovate and improve Keytruda's formulations, which could maintain market share.

Sources:

[1] Ono Pharmaceutical Co. Ltd. licensing agreement with Merck & Co. Inc. (2006)

[2] DrugPatentWatch.com - U.S. Patent Expiration Date for Pembrolizumab - Keytruda